DNAY Codex DNA, Inc.

Codex DNA, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. Its solutions include BioXp system that empowers researchers to go from a digital DNA sequence to endpoint-ready synthetic DNA; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice; BioXp kits that contain building blocks and reagents, including its Gibson Assembly branded reagents, for specific synthetic biology workflow applications; Cloud-based scripts; Benchtop reagents that contain all the reagents necessary to proceed with a specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and Biofoundry Services, which enable a customer to order and receive the BioXp system endpoint-ready products, such as genes, clones, cell-free amplified DNA, and variant libraries. The company also serves government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as SGI-DNA, Inc. and changed its name to Codex DNA, Inc. in March 2020. Codex DNA, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

$7.23  +0.51 (7.59%)
As of 12/02/2021 16:00:01 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Medical Devices
Index country:  USA
Country of incorporation:  USA
IPO date:  06/18/2021
Outstanding shares:  29,307,199
Average volume:  103,050
Market cap:   $196,944,377
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
CUSIP:    192003101
ISIN:        US1920031010
Sedol:      BNK9MX4
Valuation   (See tab for details)
PE ratio:   -8.01
PB ratio:   2.06
PS ratio:   19.89
Return on equity:   -31.19%
Net income %:   -323.67%

2021 © Stock Market MBA, Inc. Terms of use | Privacy policy